HISTOGENICS CORP (HSGX) saw its loss narrow to $7.08 million, or $0.27 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $7.92 million, or $0.60 a share.     

The company has not recorded any revenues for the current as well as previous quarter.

Operating loss for the quarter was $6.83 million, compared with an operating loss of $7.80 million in the previous year period.

"In the first quarter of 2017, we continued to execute on our important near- and long-term business objectives. Importantly, we enrolled an additional 23 patients in the NeoCart Phase 3 clinical trial, and completed a series of productive formal meetings with the PMDA in Japan where we determined a near-term regulatory pathway for NeoCart to gain full Marketing Authorization in the Japanese market," stated Adam Gridley, president and chief executive officer of Histogenics. "We are pleased to report continued strength in our enrollment of the clinical trial, which is expected to conclude this quarter. We also continue to build on our strong portfolio of bench and clinical data with several new publications on the clinical and biomechanical performance of NeoCart. This contributes to our goal of a rapid BLA filing in the second half of 2018, and helps prepare us for the potential commercialization of NeoCart in 2019, pending positive results from the NeoCart Phase 3 clinical trial and FDA approval," continued Mr. Gridley.